Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc, H Lee Moffitt Cancer Ct & ResfiledCriticalForma Therapeutics Inc
Publication of AR109858A1publicationCriticalpatent/AR109858A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente provee métodos y usos de inhibidores de histona desacetilasa 11 (HDAC11) en el tratamiento de enfermedades y/o trastornos, como, por ejemplo, enfermedades proliferativas celulares. Reivindicación 1: Un método para inhibir o reducir la proliferación de células cancerosas en un paciente que lo necesita, que comprende administrarle un inhibidor de HDAC11 al paciente.This provides methods and uses of histone deacetylase 11 (HDAC11) inhibitors in the treatment of diseases and / or disorders, such as, for example, cell proliferative diseases. Claim 1: A method of inhibiting or reducing the proliferation of cancer cells in a patient in need, comprising administering an HDAC11 inhibitor to the patient.
ARP170102934A2016-10-202017-10-20
METHODS THAT USE HDAC11 INHIBITORS
AR109858A1
(en)
compound of formula I, isolated enantiomer, pharmaceutical composition, method for inhibiting mct4 monocarboxylate transporter activity, method for selectively inhibiting mct4 monocarboxylate transporter activity, method for treating a mct4 monocarboxylate transporter mediated disorder and use of a compound